Abstract: Platinum and palladium complexes are disclosed that can be useful as narrow band phosphorescent emitters. Also disclosed are methods for preparing and using the platinum and palladium complexes.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect.

Abstract: The present invention, among other things, provides highly syndiotactic poly(dicyclopentadiene) and/or hydrogenated poly(dicyclopentadiene), compositions thereof, and compounds and methods for preparing the same. In some embodiments, a provided compound is a compound of formula I, II or III. In some embodiments, a provided method comprises providing a compound of formula I, II or III.

Abstract: Iridium (III) complexes are described together with methods to prepare and use such complexes. Also described are devices that utilize the iridium (III) complexes.

Abstract: The invention relates to electrochemical devices comprising complexes of cobalt comprising at least one ligand with a 5- or six membered, N-containing heteroring. The complex are useful as p- and n-dopants, as over of electrochemical devices, in particular in organic semiconductors. The complexes are further useful as over-discharge prevention and overvoltage protection agents.

Abstract: An iridium complex represented by formula (1) and an OLED using the same are shown. In Formula (1), l, m, n, p, b, R1-R6, X1-X6, A1, A2 and B are the same as defined in the specification. The iridium complex is able to emit a range of visible light with high color purity and high efficiency as neat sample.

Abstract: Platinum complexes that exhibit photoabsorption and photoemission, methods of making such complexes, and applications thereof are disclosed, including optical devices comprising the complexes.

Abstract: This invention provides transition metal carbene complexes and the electroluminescent application thereof. Through employing different N^N heteroleptic ligand, as the following, the transition metal carbene complex can display wide-range color tuning ability from deep blue to red. The mentioned transition metal carbene complex can be applied in luminescent device, and the luminescent device can display wide-range color tuning ability with high luminescent efficiency while employing different N^N heteroleptic ligand in the transition metal carbene complex.

Abstract: The present invention discloses novel Ruthenium (II) polypyridyl complexes, preparation and its application as DNA imaging agents.

Abstract: A hydrogen transfer reaction may be more efficiently promoted by using a metal complex represented by Formula (2): (wherein, R1 to R8 are the same or different, and each represents a hydrogen atom, a substituted or unsubstituted alkyl group or the like; or wherein; R1 and R2, R2 and R3, R3 and R4, R4 and R5, and R5 and R6 are respectively bonded to each other to form a bivalent hydrocarbon group; R9 are the same or different, and each represents an alkyl group or cycloalkyl group; M is ruthenium (Ru) or the like; X is a ligand; and n is 0, 1 or 2). More specifically, the metal complex enables a hydrogenation reaction of various substrates having a stable carbonyl group or the like to be advanced with a high yield under mild conditions.

Abstract: Novel heterocyclic materials are disclosed. The materials contain a fused tetracyclic structure that can improve the properties of OLED devices when the novel heterocyclic materials are incorporated into such devices.

Abstract: Methods of inhibiting Barrett's esophagus and/or adenocarcinoma in a subject are provided. In a particular embodiment, the method comprises administering at least one composition comprising at least one zinc compound and at least one pharmaceutically acceptable carrier to the esophagus of the subject. The zinc may be a pharmaceutically acceptable salt of zinc, such as zinc gluconate. The zinc may be administered, for example, orally, topically, or by an implantable medical device. In a particular embodiment, the methods further comprise administering at least one analgesic, anesthetic, or other therapeutic agent or therapy for the treatment of Barrett's esophagus. The method may further comprise monitoring the progression of Barrett's esophagus in the subject.

Abstract: A method of manufacturing an anhydrous copper complex of formula C12H10ClCuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, Alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (GP), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention.

Abstract: An efficient, one step solution state processing of Proton Conducting Homochiral Metal Organic Framework has been achieved by using derivate of amino acid and Zn(II) salt as a MOF constructor. Control over MOF solubility as well as proton conductivity has also been achieved by judicious selection of the ligand architecture. This invention will lead the way for ease preparation of MOF films for industrial application.

Abstract: The present invention relates to a self-assembled helical metallic complex of formula (1): [M1M2M3(L1)3] (1) said metallic complex forming a triad donor (M1)/acceptor (M2)/donor (M3), wherein the efficiency of the intermolecular energy transfer between the pair of donors (M\) and (M3) to the acceptor (M2) is from 30% to 70% and the L1 ligand-field strength of the donors (M1) and (M3) is at least 19000 cm?1.

Abstract: The present invention describes photolabile compounds and methods for use of the compounds. The photolabile compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect.

Abstract: A copper(I) complex is represented by the following Formula (1): [Cua(XS)b(L)c], wherein, L is triphenylphosphine, acetonitrile, tri-iso-butylphosphine, or a substituted or unsubstituted heterocyclic compound having 5 to 18 carbon atoms, a is an integer from 2 to 6, b is an integer from 2 to 6, c is an integer from 0 to 6, X is a substituted or unsubstituted aryl group, substituted or unsubstituted carbazole, or PR3, where R is a substituted or unsubstituted phenyl group or a substituted or unsubstituted cyclohexyl group.

Abstract: Stable and efficient organic light-emitting diodes were prepared using tetradentate platinum-based blue and red emitters. In one example, a series of stable and efficient red phosphorescent OLEDs was fabricated employing a phenyl-pyridyl-carbazole based tetradentate cyclometalated Pt(II) complex as an emitting dopant and utilizing a commercially available host, transporting, and blocking materials. By implementing this platinum complex in electrochemically stable device architectures, long operational lifetimes were achieved with an estimated LT97 of over 600 hrs at luminance of 1000 cd/m2.

Abstract: A bis-tridentate iridium complex represented by a formula (I): where R3 to R8, R21 to R23, R9, R10, X1, X2, and X3 are as defined in the specification.

Abstract: A method for obtaining, with high selectivity as compared to a conventional method of mixing reaction substrates and thereafter reacting the mixture under heating, a facial isomer of tris-orthometallated iridium that is suitably used particularly as an organic electroluminescence device material, among complexes of tris-orthometallated iridium. The method for producing a complex of tris-orthometallated iridium according to the present disclosure includes, in order, a step (1) of preliminarily heating at least one of the complex of orthometallated iridium or the bidentate organic ligand; a step (2) of mixing the complex of orthometallated iridium and the bidentate organic ligand; and a step (3) of reacting the complex of orthometallated iridium and the bidentate organic ligand.

Abstract: A platinum (II) complex of the general formula (I) or (II), in which Ar1, Ar2, and Ar3 are each independently aryl, heteroaryl, or heterocyclic. Ar1, Ar2, and Ar3 together form a tridentate ligand coordinated to the platinum through atoms X, Y, and Z, respectively, and X, Y, and Z are independently carbon or nitrogen. V is a bridging group or a covalent bond, and W is an anion. In general formula (I) in some cases, Ar1 is an anion and Ar2 and Ar3 are neutral; in other cases, Ar1 and Ar3 are neutral and Ar2 is an anion. In general formula (II), in some cases, Ar3 is an anion and Ar1 and Ar2 are neutral; in other cases, Ar1 and Ar3 are neutral and Ar2 is an anion. The complexes are asymmetric. The complexes emit in the UV to near IR range and are useful as emitters for organic light emitting devices.

Abstract: Methods are provided for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. For example, aromatic ketones and heteroaromatic ketones are reacted with hydrogen and/or a hydrogen donating compound in the presence of the ruthenium complex.

Abstract: Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising bisamineazaallylic ligands are provided. Also provided are bisamineazaallylic ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Abstract: The present invention generally relates to a novel process for preparing alkali metal pyrithione from pyridine N-oxide, using a sulfurination agent and a base agent. In particular, the present invention relates to an efficient process for preparing polyvalent metal complexes of sodium pyrithione from the alkali metal pyridine N-oxide described herein.

Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.

Abstract: A platinum complex of a formula (I): where R1 and R2 are each fluoroalkyl, X is C—H or nitrogen, and L1 is a bidentate, nitrogen-containing heteroaromatic ligand.

Abstract: A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, Alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (GP), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention.

Abstract: Disclosed herein are cobalt complexes containing terpyridine ligands and chelating alkene-modified silyl ligands, and their use as hydrosilylation and/or dehydrogenative silylation and crosslinking catalysts. The cobalt complexes also exhibit adequate air stability for handling and manipulation.

Abstract: The invention relates to a compound of the Structure 1 wherein Structure 1 contains a metal Met, coordinated to a tetradentate chelating ligand Lig of Structure 2 where V is a bridging unit which contains 1 to 40 atoms from the third, fourth, fifth and/or sixth main group and connects the two ligand moieties L1 and L2, which may be identical or different on each occurrence, covalently to one another, and where the two ligand moieties L1 and L2 satisfy Structure 3 where Cy1 and Cy2, identically or differently on each occurrence, correspond to a substituted or unsubstituted, saturated, unsaturated or aromatic homo- or heterocyclic ring, which is in each case bonded ionically, covalently or coordinatively to the metal via a ring atom or via an atom bonded exocyclically to the homo- or heterocyclic ring; and where L3, identically or differently on each occurrence, is a mono- or bidentate, neutral or monoanionic ligand, and where a is 0, 1 or 2.

Abstract: Disclosed are novel ruthenium compounds of formula (Ia) and (Ib): wherein R1 and the moiety are defined herein. Also disclosed is a process for using these novel ruthenium compounds as catalysts for asymmetric hydrogenation and transfer hydrogenation of ketones with high reactivities and excellent selectivities.

Abstract: The invention relates to copper(I) complexes of the formula A wherein X=Cl, Br or I (independently of one another); N*?E=a bidentate ligand, wherein E=a phosphinyl group including a phosphorus atom or an arsenyl group including an arsenic atom, wherein the phosphinyl group or the arsenyl group is combined with R in the form of R2E (where R=alkyl, aryl, alkoxy, or phenoxy; N*=imine function which is part of an aromatic group selected from pyridyl, pyrimidyl, pyridazinyl, triazinyl, oxazolyl, thiazolyl and imidazolyl, the aromatic group optionally having at least one substituent to increase the solubility of the copper(I) complex in an organic solvent; and ?=at least one carbon atom which is likewise part of the aromatic group. The carbon atom is located directly adjacent both to the imine nitrogen atom, coordinating to Cu in the case of a bridging ligand and to the phosphorus or arsenic atom.

Abstract: The present invention relates to a method for producing a high-molecular-weight copolymer of polar group-containing allyl monomers comprising monomer units represented by formulae (3) and (4) (in the formulae, R1 represents a hydrogen atom (H) or hydrocarbon group having 1 to 6 carbon atoms; R2 represents —OH, —OCOR3 (R3 represents hydrocarbon group having 1 to 5 carbon atoms), —N(R4)2 (R4 represents a hydrogen atom or hydrocarbon group having 1 to 5 carbon atoms); and n and m are a value representing the molar ratio of each of the monomer units), which has few branches and unsaturated group at the molecular end, by copolymerizing olefin and an allyl compound using a metal complex of group 10 elements in the periodic system represented by formula (I) as a catalyst.

Abstract: The present invention describes novel ionic metal complexes. Compounds of this type can be employed as functional materials in a number of different applications which can be ascribed to the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (1) and (1a).

Abstract: Objects of the present invention are to provide a novel dehydrogenation reaction catalyst, to provide a method that can produce a ketone, an aldehyde, and a carboxylic acid with high efficiency from an alcohol, and to provide a method for efficiently producing hydrogen from an alcohol, formic acid, or a formate, and they are accomplished by a catalyst containing an organometallic compound of Formula (1).

Abstract: In one embodiment, the present invention provides a class of luminescent gold(III) compounds containing a tridentate ligand with one strong ?-donating group. The present invention also provides methods for synthesizing these compounds, as well as uses of these compounds as electrophosphorescent materials in phosphorescent organic light-emitting devices (OLEDs) to provide electroluminescence (EL).

Abstract: A single-step method of making tetradentate platinum complexes is disclosed. The method advantageously allows the formation of a platinum complex in a single step, even with sterically hindered ligands, without the use of highly reactive intermediates. The compounds made by the disclosed method are useful in OLED applications.

Abstract: A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.

Abstract: Described herein are organometallic or inorganic complexes with high extreme ultraviolet (EUV) optical density (OD) and high mass density for use in thin films. These thin films are used as high resolution, low line edge roughness (LER) EUV photoresists. The complexes may also be included in nanoparticle form for use in photoresists.

Abstract: Described are palladium precatalysts, and methods of making and using them. The palladium precatalysts show improved stability and improved reactivity in comparison to previously-described palladium precatalysts.

Abstract: The present invention provides ruthenium or osmium complexes and their uses as a catalyst for catalytic water oxidation. Another aspect of the invention provides an electrode and photo-electrochemical cells for electrolysis of water molecules.

Abstract: A novel bidentate ligand of general formula (I) is described together with a process for the carbonylation of ethylenically unsaturated compounds. The group X1 may be defined as a univalent hydrocarbyl radical of up to 30 atoms containing at least one nitrogen atom having a pKb in dilute aqueous solution at 18° C. of between 4 and 14 wherein the said at least one nitrogen atom is separated from the Q2 atom by between 1 and 3 carbon atoms. The group X2 is defined as X1, X3 or X4 or represents a univalent radical of up to 30 atoms having at least one primary, secondary or aromatic ring carbon atom wherein each said univalent radical is joined via said at least one primary, secondary or aromatic ring carbon atom(s) respectively to the respective atom Q2. Q1 and Q2 each independently represent phosphorus, arsenic or antimony.

Abstract: A method of preparing a nitrogen containing electrode catalyst by converting a high surface area metal-organic framework (MOF) material free of platinum group metals that includes a transition metal, an organic ligand, and an organic solvent via a high temperature thermal treatment to form catalytic active sites in the MOF. At least a portion of the contained organic solvent may be replaced with a nitrogen containing organic solvent or an organometallic compound or a transition metal salt to enhance catalytic performance. The electrode catalysts may be used in various electrochemical systems, including a proton exchange membrane fuel cell.

Abstract: A composition of matter suitable for the generation of hydrogen from water is described, the positively charged cation of the composition having the general formula [(PY5W2)MO]2+, wherein PY5W2 is (NC5XYZ)(NC5H4)4C2W2, M is a transition metal, and W, X, Y, and Z can be H, R, a halide, CF3, or SiR3, where R can be an alkyl or aryl group. The two accompanying counter anions, in one embodiment, can be selected from the following Cl?, I?, PF6?, and CF3SO3?. In embodiments of the invention, water, such as tap water containing electrolyte or straight sea water can be subject to an electric potential of between 1.0 V and 1.4 V relative to the standard hydrogen electrode, which at pH 7 corresponds to an overpotential of 0.6 to 1.0 V, with the result being, among other things, the generation of hydrogen with an optimal turnover frequency of ca. 1.5 million mol H2/mol catalyst per h.

Abstract: The invention relates to platinum complexes and their use in biomedical applications, like in vitro and in vivo imaging and cell staining. The present invention provides new materials and their use as imaging agent. The formation of luminescent aggregates can allow a switch of the emission leading to a dynamic label and on the formation of soft assemblies, which, in some cases, are even more emissive than the isolated corresponding species.

Abstract: A heteroleptic iridium complex of a formula (I): where R1 and R2 are each independently hydrogen, alkyl, fluoroalkyl, or aryl, X is C-X1 or nitrogen, X1 being hydrogen or phenyl, L1 is a monoanionic bidentate ligand, and L2 is a neutral bidentate ligand.

Abstract: The present invention relates to copper, gallium and technetium coordinated thiosemicarbazone-pyridylhydrazine (substituted at the pyridine ring with a substituted benzothiazole or stilbene moiety) complexes and methods thereof. Such compounds possess utility in PET imaging and diagnosis of amyloid diseases.

Abstract: Platinum complexes that exhibit photoabsorption and photoemission, methods of making such complexes, and applications thereof are disclosed, including optical devices comprising the complexes.

Abstract: The invention relates to a series of novel chiral nitrogen-phosphorus ligands of formulae (Ia) and (Ib): wherein R1-R3 and X are as defined herein. The invention also relates to chiral metal complexes prepared with these chiral nitrogen-phosphorus ligands. The chiral metal complexes are useful as catalysts for carrying out asymmetric hydrogenation.

Abstract: Embodiments include selective adsorbents having a structure of Formula (I) where a connection to X represents a connection to a structure of Formula (II), and a connection to Y represents a connection to a structure of Formula (III), where each R1 is independently selected from the group consisting of fluorine, chlorine, bromine, and iodine, and each R2 is independently selected from the group consisting of a hydrogen, an alkyl, an aryl, and a trisubstitutedsilyl group.

Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.